Seroatlas · Human Serome Atlas

NCR3

Natural cytotoxicity triggering receptor 3

Also known as: 1C7, CD337, LY117, NCTR3_HUMAN, NKp30

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O14931
Gene
NCR3
Ensembl
ENSG00000204475
Chromosome
6
Canonical length
201 aa
Protein class
CD markers, Predicted membrane proteins
Quaternary structure
Homodimer

OverviewNCBI Gene

The protein encoded by this gene is a natural cytotoxicity receptor (NCR) that may aid NK cells in the lysis of tumor cells. The encoded protein interacts with CD3-zeta (CD247), a T-cell receptor. A single nucleotide polymorphism in the 5' untranslated region of this gene has been associated with mild malaria suceptibility. Three transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, May 2010]

Canonical amino-acid sequenceUniProt

201 residues, UniProt reviewed canonical sequence.

>O14931|NCR3
     1  MAWMLLLILI MVHPGSCALW VSQPPEIRTL EGSSAFLPCS FNASQGRLAI GSVTWFRDEV
    61  VPGKEVRNGT PEFRGRLAPL ASSRFLHDHQ AELHIRDVRG HDASIYVCRV EVLGLGVGTG
   121  NGTRLVVEKE HPQLGAGTVL LLRAGFYAVS FLSVAVGSTV YYQGKCLTWK GPRRQLPAVV
   181  PAPLPPPCGS SAHLLPPVPG G

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NCR3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.44
Highest tissue expression
16 nTPM

Expression across tissuesHPA

Tissue

  • spleen: 16 nTPM
  • small intestine: 5.2 nTPM
  • lymph node: 5.1 nTPM
  • tonsil: 4.6 nTPM
  • bone marrow: 3.8 nTPM
  • appendix: 2.7 nTPM

Single-cell type

  • nk-cells: 45 nCPM
  • innate lymphoid cells: 17 nCPM
  • t-cells: 13 nCPM
  • b-cells: 11 nCPM
  • medullary thymic epithelial cells: 2.4 nCPM
  • kupffer cells: 2 nCPM

Immune cell

  • MAIT T-cell: 275 nTPM
  • gdT-cell: 99 nTPM
  • NK-cell: 77 nTPM
  • memory B-cell: 66 nTPM
  • memory CD8 T-cell: 54 nTPM
  • naive B-cell: 52 nTPM

Brain region

  • cerebral cortex: 0.3 nTPM
  • medulla oblongata: 0.2 nTPM
  • pons: 0.2 nTPM
  • thalamus: 0.2 nTPM
  • white matter: 0.2 nTPM
  • amygdala: 0.1 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about NCR3.

Disease | GeneticClinVar

2 pathogenic / likely-pathogenic of 38 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

ReferencesPubMed · IEDB

Publications for NCR3 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

1 publication

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.45
gnomAD pLI
0
gnomAD missense Z
0.82
DepMap mean gene effect
-0.02
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of NCR3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NCR3 as an antibody target. Whether an autoantibody or antibody against NCR3 could matter depends on whether native NCR3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NCR3 is annotated at the cell surface, where native NCR3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label NCR3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/NCR3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...